柏 宗伸

Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan 

Clinical Drug Investigation 2024年9月21日  

Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer 

Journal of Gastrointestinal Cancer 2024年8月22日  

Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan. 

The European journal of health economics : HEPAC : health economics in prevention and care 2023年6月1日  

Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer 

International Journal of Clinical Pharmacy 2023年4月20日  

Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan. 

Biological & pharmaceutical bulletin 45(7) 895-903 2022年  

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan. 

Journal of pharmaceutical health care and sciences 7(1) 35-35 2021年10月1日  

Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. 

Clinical therapeutics 42(7) 1361-1375 2020年7月  

Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. 

Clinical therapeutics 42(7) 1376-1387 2020年7月  

Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan. 

BMC health services research 19(1) 438-438 2019年7月1日  

Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. 

Clinical therapeutics 41(5) 929-942 2019年5月